A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma.

Daniel Chiu, Jingjing Qi,Tin Htwe Thin,Monica Garcia-Barros, Brian Lee,Mary Hahn,John Mandeli,Puneet Belani, Kambiz Nael,Omid Rashidipour,Saadi Ghatan,Constantinos G Hadjipanayis,Raymund L Yong,Isabelle M Germano,Rachel Brody,Nadejda M Tsankova,Sacha Gnjatic,Seunghee Kim-Schulze,Adília Hormigo

Cancer research communications（2023）

引用 0|浏览1

暂无评分

摘要

Our phase I of PD-L1 inhibition combined with LITT and using bevacizumab to spare steroids had a good safety profile for recurrent GBM. Developing combinatory treatment may help outcomes. In addition, we found significant immune modulation of cytokines and immune cells by bevacizumab, which may enhance the effect of ICI.

查看译文

关键词

glioblastoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要